"uuid:ID","id","instanceType","rationale","description","name","label"
"81a60752-82b7-4155-912e-f5c18ecbdbc2","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1",""
